Close

Can-Fite BioPharma (CANF) Announces Submission of CF102 Phase 2 Protocol as NAFLD/NASH Treatment

Go back to Can-Fite BioPharma (CANF) Announces Submission of CF102 Phase 2 Protocol as NAFLD/NASH Treatment
CAN-FITE BIOPHARMA LTD. (NYSE: CANF) Delayed: 1.97 -0.01 (0.51%)
Previous Close $1.98    52 Week High $3.89 
Open $1.96    52 Week Low $1.85 
Day High $1.98    P/E N/A 
Day Low $1.96    EPS $0.00 
Volume 3,761       

(NASDAQ: CFBI) Delayed: 10.08 --0 (-0%)
Previous Close $10.08    52 Week High
Open $41.64    52 Week Low
Day High $10.08    P/E N/A 
Day Low $10.08    EPS
Volume 206